CRYOPORT, INC. Selling and Marketing Expense
CRYOPORT, INC. (CYRX) reported Selling and Marketing Expense of $3.68 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2020-11-06
- CRYOPORT, INC. selling and marketing expense for the quarter ending 2020-09-30 was $3.68M, a 38.24% decline year-over-year.
- CRYOPORT, INC. selling and marketing expense for the quarter ending 2020-06-30 was $3.29M, a 15.82% increase year-over-year.
- CRYOPORT, INC. selling and marketing expense for the quarter ending 2020-03-31 was $3.08M, a 27.97% increase year-over-year.
- CRYOPORT, INC. selling and marketing expense for the quarter ending 2019-12-31 was $2.61M, a 31.11% increase year-over-year.
- CRYOPORT, INC. selling and marketing expense for fiscal 2019 was $13.82M, a 90.75% increase from fiscal 2018.
- CRYOPORT, INC. selling and marketing expense for fiscal 2018 was $7.25M, a 38.48% increase from fiscal 2017.
- CRYOPORT, INC. selling and marketing expense for fiscal 2017 was $5.23M, a 8.55% increase from fiscal 2016.
- CRYOPORT, INC. selling and marketing expense for fiscal 2016 was $4.82M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2020-09-30 | $3.68M 10-Q · filed 2020-11-06 | $6.97M derived: sum of 2 quarters · filed 2020-11-06 | $10.06M 10-Q · filed 2020-11-06 | $12.66M derived: sum of 4 quarters · filed 2020-11-06 |
| 2020-06-30 | $3.29M 10-Q · filed 2020-08-10 | $6.37M 10-Q · filed 2020-08-10 | $8.98M derived: sum of 3 quarters · filed 2020-08-10 | $14.94M derived: sum of 4 quarters · filed 2020-11-06 |
| 2020-03-31 | $3.08M 10-Q · filed 2020-05-08 | $5.69M derived: sum of 2 quarters · filed 2020-05-08 | $11.65M derived: sum of 3 quarters · filed 2020-11-06 | $14.49M derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $8.57M derived: sum of 2 quarters · filed 2020-11-06 | $11.41M derived: sum of 3 quarters · filed 2020-11-06 | $13.82M 10-K · filed 2020-03-10 |
| 2019-09-30 | $5.96M 10-Q · filed 2020-11-06 | $8.80M derived: sum of 2 quarters · filed 2020-11-06 | $11.21M 10-Q · filed 2020-11-06 | $13.20M derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-06-30 | $2.84M 10-Q · filed 2020-08-10 | $5.25M 10-Q · filed 2020-08-10 | $7.24M derived: sum of 3 quarters · filed 2020-08-10 | $9.06M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $2.41M 10-Q · filed 2020-05-08 | $4.40M derived: sum of 2 quarters · filed 2020-05-08 | $6.22M derived: sum of 3 quarters · filed 2020-05-08 | $8.07M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $3.81M derived: sum of 2 quarters · filed 2020-03-10 | $5.66M derived: sum of 3 quarters · filed 2020-03-10 | $7.25M 10-K · filed 2020-03-10 |
| 2018-09-30 | $1.82M 10-Q · filed 2019-11-12 | $3.67M derived: sum of 2 quarters · filed 2019-11-12 | $5.26M 10-Q · filed 2019-11-12 | $6.83M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $1.85M 10-Q · filed 2019-08-09 | $3.44M 10-Q · filed 2019-08-09 | $5.01M derived: sum of 3 quarters · filed 2019-08-09 | $6.36M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $1.58M 10-Q · filed 2019-05-09 | $3.16M derived: sum of 2 quarters · filed 2019-05-09 | $4.51M derived: sum of 3 quarters · filed 2019-05-09 | $5.75M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $2.93M derived: sum of 2 quarters · filed 2019-03-13 | $4.16M derived: sum of 3 quarters · filed 2019-03-13 | $5.23M 10-K · filed 2019-03-13 |
| 2017-09-30 | $1.35M 10-Q · filed 2018-11-08 | $2.59M derived: sum of 2 quarters · filed 2018-11-08 | $3.66M 10-Q · filed 2018-11-08 | $4.80M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $1.24M 10-Q · filed 2018-08-09 | $2.31M 10-Q · filed 2018-08-09 | $3.45M derived: sum of 3 quarters · filed 2018-08-09 | $4.68M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $1.07M 10-Q · filed 2018-05-03 | $2.21M derived: sum of 2 quarters · filed 2018-05-03 | $3.45M derived: sum of 3 quarters · filed 2018-05-03 | $4.64M derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $1.14M derived: 10-K 9 month − 10-Q 6 month · filed 2018-03-08 | $2.38M derived: sum of 2 quarters · filed 2018-03-08 | $3.57M 10-K · filed 2018-03-08 | $4.82M 10-K · filed 2018-03-08 |
| 2016-09-30 | $1.24M 10-Q · filed 2017-11-02 | $2.43M 10-Q · filed 2016-11-14 | $3.68M 10-Q · filed 2017-11-02 | $4.80M derived: sum of 4 quarters · filed 2017-11-02 |
| 2016-06-30 | $1.20M 10-Q · filed 2017-08-09 | $2.44M 10-Q · filed 2017-08-09 | $3.57M derived: sum of 3 quarters · filed 2017-08-09 | $4.47M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $1.25M 10-Q · filed 2017-05-04 | $2.37M derived: sum of 2 quarters · filed 2017-05-04 | $3.27M derived: sum of 3 quarters · filed 2017-05-04 | $4.16M 10-KT · filed 2017-03-13 |
| 2015-12-31 | $1.13M derived: 10-KT 9 month − 10-Q 6 month · filed 2017-03-13 | $2.02M derived: sum of 2 quarters · filed 2017-03-13 | $2.91M 10-KT · filed 2017-03-13 | |
| 2015-09-30 | $897.27K 10-Q · filed 2016-11-14 | $1.78M 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | $884.61K 10-Q · filed 2016-08-15 | |||
| 2015-03-31 | $2.91M 10-K · filed 2016-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |